Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma.

Authors:
Chen D; Li Q; Xu Y; Wei Y; Li J and 5 more

Journal:
Cancer Cell Int

Publication Year: 2023

DOI:
10.1186/s12935-023-03147-7

PMCID:
PMC10709922

PMID:
38066643

Journal Information

Full Title: Cancer Cell Int

Abbreviation: Cancer Cell Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe First Affiliated Hospital of Zhengzhou University’s Ethics Committee approved this study in accordance with the Declaration of Helsinki (Approval Number: 2019-KY-176). Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Funding Henan Natural Science Fund Project, China [grant number 212300410401] funded this research."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025